BACKGROUND: We investigated the use of deep brain stimulation (DBS) of the ventral capsule/ventral striatum (VC/VS) for treatment refractory depression. METHODS: Fifteen patients with chronic, severe, highly refractory depression received open-label DBS at three collaborating clinical sites. Electrodes were implanted bilaterally in the VC/VS region. Stimulation was titrated to therapeutic benefit and the absence of adverse effects. All patients received continuous stimulation and were followed for a minimum of 6 months to longer than 4 years. Outcome measures included the Hamilton Depression Rating Scale-24 item (HDRS), the Montgomery-Asberg Depression Rating Scale (MADRS), and the Global Assessment of Function Scale (GAF). RESULTS: Significant improvements in depressive symptoms were observed during DBS treatment. Mean HDRS scores declined from 33.1 at baseline to 17.5 at 6 months and 14.3 at last follow-up. Similar improvements were seen with the MADRS (34.8, 17.9, and 15.7, respectively) and the GAF (43.4, 55.5, and 61.8, respectively). Responder rates with the HDRS were 40% at 6 months and 53.3% at last follow-up (MADRS: 46.7% and 53.3%, respectively). Remission rates were 20% at 6 months and 40% at last follow-up with the HDRS (MADRS: 26.6% and 33.3%, respectively). The DBS was well-tolerated in this group. CONCLUSIONS: Deep brain stimulation of the VC/VS offers promise for the treatment of refractory major depression.
BACKGROUND: We investigated the use of deep brain stimulation (DBS) of the ventral capsule/ventral striatum (VC/VS) for treatment refractory depression. METHODS: Fifteen patients with chronic, severe, highly refractory depression received open-label DBS at three collaborating clinical sites. Electrodes were implanted bilaterally in the VC/VS region. Stimulation was titrated to therapeutic benefit and the absence of adverse effects. All patients received continuous stimulation and were followed for a minimum of 6 months to longer than 4 years. Outcome measures included the Hamilton Depression Rating Scale-24 item (HDRS), the Montgomery-Asberg Depression Rating Scale (MADRS), and the Global Assessment of Function Scale (GAF). RESULTS: Significant improvements in depressive symptoms were observed during DBS treatment. Mean HDRS scores declined from 33.1 at baseline to 17.5 at 6 months and 14.3 at last follow-up. Similar improvements were seen with the MADRS (34.8, 17.9, and 15.7, respectively) and the GAF (43.4, 55.5, and 61.8, respectively). Responder rates with the HDRS were 40% at 6 months and 53.3% at last follow-up (MADRS: 46.7% and 53.3%, respectively). Remission rates were 20% at 6 months and 40% at last follow-up with the HDRS (MADRS: 26.6% and 33.3%, respectively). The DBS was well-tolerated in this group. CONCLUSIONS: Deep brain stimulation of the VC/VS offers promise for the treatment of refractory major depression.
Authors: Helen S Mayberg; Andres M Lozano; Valerie Voon; Heather E McNeely; David Seminowicz; Clement Hamani; Jason M Schwalb; Sidney H Kennedy Journal: Neuron Date: 2005-03-03 Impact factor: 17.173
Authors: Koenraad Van Laere; Bart Nuttin; Loes Gabriels; Patrick Dupont; Steve Rasmussen; Benjamin D Greenberg; Paul Cosyns Journal: J Nucl Med Date: 2006-05 Impact factor: 10.057
Authors: H S Mayberg; M Liotti; S K Brannan; S McGinnis; R K Mahurin; P A Jerabek; J A Silva; J L Tekell; C C Martin; J L Lancaster; P T Fox Journal: Am J Psychiatry Date: 1999-05 Impact factor: 18.112
Authors: A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava Journal: Am J Psychiatry Date: 2006-11 Impact factor: 18.112
Authors: Benjamin D Greenberg; Lawrence H Price; Scott L Rauch; Gerhard Friehs; Georg Noren; Donald Malone; Linda L Carpenter; Ali R Rezai; Steven A Rasmussen Journal: Neurosurg Clin N Am Date: 2003-04 Impact factor: 2.509
Authors: B D Greenberg; L A Gabriels; D A Malone; A R Rezai; G M Friehs; M S Okun; N A Shapira; K D Foote; P R Cosyns; C S Kubu; P F Malloy; S P Salloway; J E Giftakis; M T Rise; A G Machado; K B Baker; P H Stypulkowski; W K Goodman; S A Rasmussen; B J Nuttin Journal: Mol Psychiatry Date: 2008-05-20 Impact factor: 15.992
Authors: Darin D Dougherty; Anthony P Weiss; G Rees Cosgrove; Nathaniel M Alpert; Edwin H Cassem; Andrew A Nierenberg; Bruce H Price; Helen S Mayberg; Alan J Fischman; Scott L Rauch Journal: J Neurosurg Date: 2003-12 Impact factor: 5.115
Authors: Thomas E Schlaepfer; Michael X Cohen; Caroline Frick; Markus Kosel; Daniela Brodesser; Nikolai Axmacher; Alexius Young Joe; Martina Kreft; Doris Lenartz; Volker Sturm Journal: Neuropsychopharmacology Date: 2007-04-11 Impact factor: 7.853
Authors: James M Broadway; Paul E Holtzheimer; Matthew R Hilimire; Nathan A Parks; Jordan E Devylder; Helen S Mayberg; Paul M Corballis Journal: Neuropsychopharmacology Date: 2012-03-14 Impact factor: 7.853
Authors: Wayne K Goodman; Kelly D Foote; Benjamin D Greenberg; Nikki Ricciuti; Russell Bauer; Herbert Ward; Nathan A Shapira; Sam S Wu; Candy L Hill; Stephen A Rasmussen; Michael S Okun Journal: Biol Psychiatry Date: 2010-02-08 Impact factor: 13.382
Authors: Maher A Quraan; Andrea B Protzner; Zafiris J Daskalakis; Peter Giacobbe; Chris W Tang; Sidney H Kennedy; Andres M Lozano; Mary P McAndrews Journal: Neuropsychopharmacology Date: 2013-11-28 Impact factor: 7.853
Authors: Matthew D Johnson; Hubert H Lim; Theoden I Netoff; Allison T Connolly; Nessa Johnson; Abhrajeet Roy; Abbey Holt; Kelvin O Lim; James R Carey; Jerrold L Vitek; Bin He Journal: IEEE Trans Biomed Eng Date: 2013-02-01 Impact factor: 4.538
Authors: Brady D Nelson; Zachary P Infantolino; Daniel N Klein; Greg Perlman; Roman Kotov; Greg Hajcak Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-08-07